Brief: Zealand Pharma Q1 EBIT Loss DKK 539 Mln
May 7 (Reuters) - Zealand Pharma A/S ZELA.CO: Q1 REVENUE DKK 34 MILLION Q1 EBIT DKK LOSS 539 MILLION VERSUS IBES ESTIMATE LOSS DKK 672.37 MILLION 2026 OUTLOOK: UNCHANGED 2026 OUTLOOK: RECOGNISES USD 700 MILLION / DKK 4.5 BILLION AS COLLABORATION REVENUE IN Q2 OF 2026 Source text: ID:nGNE7xp7g4 Further company coverage: ZELA.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Zealand Pharma A/S
See all newsZealand falls as Berenberg cuts to 'hold' on fading survodutide hopes
Europe Research Roundup: Aixtron, Lenzing, Novo Nordisk
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Focus: Lilly stays ahead of the pack as rivals jump on obesity drug bandwagon
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up